Department of Internal Medicine, New York Medical College - Metropolitan Hospital Center, New York, NY, USA.
Department of Cardiovascular Research, Cleveland Clinic, Akron, OH, USA.
Indian Heart J. 2021 Jan-Feb;73(1):129-131. doi: 10.1016/j.ihj.2020.12.003. Epub 2020 Dec 7.
Major consequences of untreated severe mitral regurgitation (MR) includes heart failure, ventricular remodeling and pulmonary hypertension leading to significant morbidity and mortality. MitraClip is the most widely used device for treatment of severe MR. To overcome some of the shortcomings of MitraClip, novel devices like PASCAL mitral valve repair system are developed. We performed a single arm meta-analysis for patients with severe mitral regurgitation (MR) undergoing PASCAL mitral valve repair system. The results showed that 93.8% patients had reduction in MR grade, with an average operative time of 88 min and an average increase of 86.33 m in 6-min walk test.
未经治疗的重度二尖瓣反流（MR）的主要后果包括心力衰竭、心室重构和肺动脉高压，导致发病率和死亡率显著增加。MitraClip 是治疗重度 MR 最广泛使用的装置。为了克服 MitraClip 的一些缺点，开发了新型装置，如 PASCAL 二尖瓣修复系统。我们对接受 PASCAL 二尖瓣修复系统治疗的重度二尖瓣反流（MR）患者进行了单臂荟萃分析。结果显示，93.8%的患者 MR 分级降低，平均手术时间为 88 分钟，6 分钟步行试验平均增加 86.33 米。
